| Cat.No. | Name | Information |
|---|---|---|
| M5986 | Suramin sodium salt | Suramin Sodium Salt (Suramin hexasodium salt) is a reversible inhibitor of competitive protein tyrosine phosphatases (PTPases). |
| M42218 | TNP-ATP triethylammonium | TNP-ATP triethylammonium is a selective P2X receptor antagonist. |
| M42217 | Oxidized ATP trisodium salt | Oxidized ATP (oATP) trisodium salt is a broad-spectrum P2 receptor inhibitor. |
| M42216 | P2X3 antagonist 38 | P2X3 antagonist 38 is a potent and orally active P2X3 antagonist with IC50 values of 0.132, 0.165, 0.421 µM for hP2X3, rP2X3, gpP2X3, respectively. |
| M42215 | AZ 11645373 | AZ11645373 is a highly selective and potent antagonist at human P2X7 receptors, AZ11645373 inhibits ATP-evoked IL-1β release from lps-activated THP-1 cells , with an IC50 value of 90 nM. |
| M41902 | NF546 hydrate | NF546 (hydrate) is a selective non-nucleotide P2Y11 agonist with a pEC50 of 6.27. |
| M41901 | PSB-1114 triethylamine | PSB-1114 triethylamine is a potent, enzymatically stable, and subtype-selective P2Y2 receptor agonist with an EC50 of 134 nM. |
| M40735 | 4-Thiouridine 5′-triphosphate tetralithium | 4-Thiouridine 5′-triphosphate tetralithium is a potent agonist of P2Y2 and P2Y4 with EC50 values of 35 and 350 nM for hP2Y2 and hP2Y4, respectively, and can be used in cross-linking experiments, and studies related to the labeling of transcription complexes. |
| M38965 | N6-(4-Hydroxybenzyl)adenosine | N6-(4-Hydroxybenzyl)adenosine is a inhibitor of platelet aggregation induced in vitro by collagen and their activity range was demonstrated (IC50: 6.77-141 μM). |
| M30303 | YM-254890 | YM-254890 is a selective Gαq/11 protein inhibitor isolated from Chromobacterium sp. YM-254890 shows no inhibition of other G protein subtypes. YM-254890 inhibits platelet aggregation induced by ADP by blocking the P2Y1 signal transduction pathway, with an IC50 value below 0.6 μM. |
| M29626 | P2X3 antagonist 34 | P2X3 antagonist 34 is a potent, selective and orally active P2X3 homotrimeric receptor antagonist with IC50s of 25 nM, 92 nM and 126 nM for human P2X3, rat P2X3 and guinea pig P2X3 receptors, respectively. P2X3 antagonist 34 is less active against human, rat and guinea pig P2X2/3 heterotrimeric receptors. P2X3 antagonist 34 has strong anti-tussive effect. |
| M29500 | Gefapixant citrate | Gefapixant citrate is an orally active and potent purinergic P2X3 receptor (P2X3R) antagonist, with IC50 values of ~30 nM versus recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors. Gefapixant citrate can be used for the research of chronic cough and knee osteoarthritis. |
| M29316 | JNJ-55308942 | JNJ-55308942 is a high-affinity, selective, brain-penetrant P2X7 functional antagonist (hP2X7: IC50=10 nM, Ki=7.1 nM; rP2X7: IC50=15 nM, Ki=2.9 nM). JNJ-55308942 is orally bioavailable, binds to brain P2X7 and blocks IL-1β release from adult rodent brain. |
| M29218 | Lu AF27139 | Lu AF27139 is a potent, selective, and orally active antagonist of P2X7 receptor (IC50s of 12 and 2.4 nM for human and rat, Kis of 22, 54, and 13 nM for mouse, human, and rat, respectively). Lu AF27139 has rodent-active and CNS-penetrant character. Lu AF27139 has the potential for the research of CNS diseases. |
| M29114 | NF340 | NF340 is a potent and selective P2Y11 receptor antagonist. NF340 inhibits the activity of P2Y11R by completely combining with ATP-binding amino acid residues. NF340 ameliorates inflammation in human fibroblast-like synoviocytes and can be used for rheumatoid arthritis research. |
| M28719 | (S)-JNJ-54166060 | (S)-JNJ-54166060 is an enantiomer of JNJ 54166060. JNJ 54166060 is a potent P2X7 antagonist. |
| M27619 | NF546 | NF546 is a selective non-nucleotide P2Y11 agonist with a pEC50 of 6.27. NF546 stimulates release of interleukin-8 from human monocyte-derived dendritic cells. |
| M21206 | ACT-246475 (Selatogrel) | ACT-246475 is a new reversible, selective, and potent antagonist of the platelet P2Y12 receptor. |
| M21200 | Sivopixant | The P2X3 ligand-gated ion channel antagonist sivopixant (S-600918) is an oral phase II candidate compound for the study of refractory chronic cough. |
| M19177 | Bullatine A | Bullatine A is a potent P2X7 antagonist, inhibits ATP-induced cell death/apoptosis and P2X receptor-mediated inflammatory responses. Bullatine A attenuates pain hypersensitivity, regardless of the pain models employed. |
| M14247 | PPADS | PPADS is a non-selective P2X receptor antagonist. PPADS acts as an ATP (nucleotide) mimetic and competes with ATP for its binding site on P2 receptors. PPADS is also a reversible competitive antagonist of the NAADP receptor. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
